Gossamer Bio, Inc.
A clinical-stage biopharmaceutical company based in San Diego, Gossamer Bio develops treatments for rare diseases like pulmonary arterial hypertension (PAH), a progressive condition of high blood pressure in the lungs. Its lead drug candidate, seralutinib, is an inhaled dry-powder medicine designed to be breathed directly into the lungs. Founded in 2015, the company takes its name from the gossamer thread, meant to symbolize the fragile yet vital connections it builds with patients and partners.
Granted 1.26M · Bought 1.39M · Sold 42.2K
Granted 223.0K · Bought 25.4K · Sold 17.2K
Granted 351.0K · Bought 418.9K · Sold 17.2K
Granted 256.3K · Sold 30.5K
Granted 256.3K · Bought 25.0K
Granted 209.5K · Sold 25.0K
Bought 6.9K · Sold 28.4K
Bought 58.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hasnain FaheemPresident & CEO, Director · 10 transactions | +71.5% | 6.25M | 1.26M | 1.39M | 42.2K |
| Christian WaageEVP, Tech Ops and Admin · 7 transactions | +42.9% | 882.2K | 223.0K | 25.4K | 17.2K |
| Giraudo BryanCOO/CFO · 10 transactions | +643.3% | 869.7K | 351.0K | 418.9K | 17.2K |
| Aranda RichardChief Medical Officer · 10 transactions | — | 465.6K | 256.3K | — | 30.5K |
| Smith Robert Paul JRChief Commercial Officer · 3 transactions | — | 285.9K | 256.3K | 25.0K | — |
| Peterson CarynEVP, Regulatory Affairs · 7 transactions | +305.2% | 259.3K | 209.5K | — | 25.0K |
| Carter LauraChief Scientific Officer · 7 transactions | -21.9% | 76.3Kas of Mar 2023 | — | 6.9K | 28.4K |
| Milligan SandraDirector · 2 transactions | — | 58.0Kas of Aug 2025 | — | 58.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +1.76M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.